Legal Advantage Investments Inc. Invests $591,000 in Natera, Inc. $NTRA

Key Points

• Legal Advantage Investments Inc. has invested approximately $591,000 in Natera, Inc. by purchasing 3,500 shares, indicating strong institutional interest in the medical research company.
• Analyst ratings on Natera are mixed, with Barclays upgrading the target price to $210.00 while Weiss Ratings issued a "sell" rating; overall, the stock has a consensus rating of "Moderate Buy."
• Natera's recent quarterly results showed a revenue increase of 32.2% year-over-year, although it reported a loss with an EPS of ($0.74), missing analyst expectations.

Legal Advantage Investments Inc. purchased a new position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 3,500 shares of the medical research company's stock, valued at approximately $591,000.

A number of other institutional investors and hedge funds have also made changes to their positions in NTRA. GAMMA Investing LLC increased its stake in shares of Natera by 32.3% during the first quarter. GAMMA Investing LLC now owns 848 shares of the medical research company's stock worth $120,000 after acquiring an additional 207 shares during the period. Exchange Traded Concepts LLC grew its position in Natera by 15.6% during the first quarter. Exchange Traded Concepts LLC now owns 6,458 shares of the medical research company's stock worth $913,000 after buying an additional 871 shares during the period. Precision Wealth Strategies LLC acquired a new position in Natera during the first quarter worth about $803,000. QRG Capital Management Inc. grew its position in Natera by 1.5% during the first quarter. QRG Capital Management Inc. now owns 5,417 shares of the medical research company's stock worth $766,000 after buying an additional 81 shares during the period. Finally, Rakuten Securities Inc. grew its position in Natera by 117.8% during the first quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company's stock worth $31,000 after buying an additional 119 shares during the period. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, CFO Michael Burkes Brophy sold 3,045 shares of the company's stock in a transaction that occurred on Tuesday, July 29th. The shares were sold at an average price of $137.40, for a total transaction of $418,383.00. Following the transaction, the chief financial officer owned 65,430 shares of the company's stock, valued at approximately $8,990,082. This represents a 4.45% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Rowan E. Chapman sold 2,750 shares of the company's stock in a transaction that occurred on Thursday, August 28th. The shares were sold at an average price of $166.99, for a total transaction of $459,222.50. Following the transaction, the director directly owned 6,015 shares in the company, valued at $1,004,444.85. The trade was a 31.37% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 72,464 shares of company stock worth $10,963,125. 5.63% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

NTRA has been the topic of several recent analyst reports. Barclays restated an "overweight" rating and set a $210.00 target price (up from $190.00) on shares of Natera in a research report on Friday, August 8th. Weiss Ratings restated a "sell (d-)" rating on shares of Natera in a research report on Wednesday. Royal Bank Of Canada set a $268.00 target price on shares of Natera and gave the stock an "outperform" rating in a research report on Tuesday, September 2nd. Evercore ISI upgraded shares of Natera to a "strong-buy" rating and set a $170.00 target price on the stock in a research report on Monday, July 28th. Finally, Cowen restated a "buy" rating on shares of Natera in a research report on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $192.88.

Natera Price Performance

NTRA stock opened at $169.27 on Friday. The company's 50 day simple moving average is $164.58 and its 200-day simple moving average is $157.27. The firm has a market capitalization of $23.23 billion, a PE ratio of -88.62 and a beta of 1.74. Natera, Inc. has a 12 month low of $117.27 and a 12 month high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The medical research company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.14). The business had revenue of $546.60 million during the quarter, compared to analyst estimates of $476.84 million. Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The firm's revenue for the quarter was up 32.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.30) earnings per share. Natera has set its FY 2025 guidance at EPS. As a group, sell-side analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current year.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.